Your browser doesn't support javascript.
Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase1).
Harrison, Stephanie Rose; Garrido-Cumbrera, Marco; Navarro-Compán, Victoria; Correa-Fernández, José; Webb, Dale; Christen, Laura; Marzo-Ortega, Helena.
  • Harrison SR; National Institute of Health Research (NIHR) Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust.
  • Garrido-Cumbrera M; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK.
  • Navarro-Compán V; Health and Territory Research, Universidad de Sevilla, Seville, Spain.
  • Correa-Fernández J; Axial Spondyloarthritis International Federation (ASIF), London, UK.
  • Webb D; Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
  • Christen L; Health and Territory Research, Universidad de Sevilla, Seville, Spain.
  • Marzo-Ortega H; National Ankylosing Spondylitis Society (NASS), London, UK.
Rheumatol Adv Pract ; 5(3): rkab098, 2021.
Article in English | MEDLINE | ID: covidwho-1605246
ABSTRACT

OBJECTIVES:

The aim was to compare the impact of the first wave of the coronavirus disease 2019 (COVID-19) pandemic and lockdown measures on patients with rheumatic and musculoskeletal diseases (RMDs) in the UK and other European countries (OEC).

METHODS:

REUMAVID was an online cross-sectional survey of seven European countries. The data collected included the following demographics, lifestyle, employment, access to health-care services, disease-specific characteristics, the World Health Organization five well-being index (WHO-5), hospital anxiety and depression scale (HADS), visual analogue scale (VAS) disease activity, and the perceived acceptable symptom scale.

RESULTS:

One thousand eight hundred responses were received between April and July 2020 [UK, n = 558 (31.0%); OEC, n = 1242 (69.0%)]. UK patients were more likely to be older [mean (S.d.) UK 58.5 (13.4) years; OEC 50.0 (12.2) years], university educated [UK n = 302 (54.1%); OEC n = 572 (46.1%), quit smoking [UK n = 92 (59.4%); OEC n = 65 (16.2%)] and continue exercise [UK, n = 216 (49.2%); OEC, n = 228 (33.1%)], although, conversely, alcohol consumption increased [UK n = 99 (36.3%); OEC n = 98 (12.1%)]. UK patients felt informed about COVID-19 (UK 72.7%, OEC 57.4%) and kept their planned rheumatology [UK n = 87 (51.2%); OEC n = 213 (38.6%)] and/or general practice appointments [UK n = 87 (76.3%); OEC n = 310 (53.9%)]. Almost half the patients with RMDs reported a decline in health and well-being, although this was less common in UK patients [UK n = 214 (38.4%), OEC n = 618 (50.2%)], who reported better perceived acceptable symptom scale, VAS pain and HADS scores, but worse WHO-5 scores.

CONCLUSIONS:

UK RMD patients performed better in the physical and mental health domains tested, possibly owing to a less restrictive lockdown and better health-care access. These findings have implications for health-care services globally in planning patient care after the COVID-19 pandemic.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Rheumatol Adv Pract Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Rheumatol Adv Pract Year: 2021 Document Type: Article